# US 5,352,460 A · Compositions of gastric acid-resistant microspheres containing salts of bile acids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,352,460 A
- Document ID: US5352460A
- Status: Granted
- Kind: A
- Application number: 08/065,780
- Filed: 1993-05-24
- Granted: 1994-10-04
- Earliest claimed: 1992-06-22
- Assignees: Digestive Care Inc.
- Inventors: Tibor Sipos
- Web page: https://patentgrep.com/patent/US5352460A

## CPC

- A61K 31/575: substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
- A61K 9/1605: {Excipients; Inactive ingredients}
- A61K 9/5042: {Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 25/32: Alcohol-abuse
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are gastric acid-resistant polymer-coated ursodeoxycholate compositions, process for their preparations and methods of treating digestive disorders, impaired liver function, autoimmune diseases of the liver and biliary tract, prevention of colon cancer following cholecystectomy, cystic fibrosis, dissolving gallstones and regulating dietary cholesterol absorption by administering said compositions to a mammal in need of such treatment.

## Claims

### Claim 1

A process for preparing a ursodeoxycholate composition for the treatment of ursodeoxycholic acid deficient mammals comprising the steps of:
a) blending dry, powdery ingredients selected from the group consisting of (i) from about 60 to about 89% w/w of a salt of UDCA selected from the group consisting of sodium, potassium, ammonium, tromethamine, ethanolamine, diethanolamine and triethanolamine; (ii) up to about 5% of a buffering agent selected from the group consisting of from about 0.25 to about 5.0% w/w sodium carbonate (anhydrous), sodium bicarbonate, potassium carbonate and potassium bicarbonate and from about 0.25 to about 1.5% w/w, tromethamine, diethanolamine and triethanolamine; (iii) of from about 2 to about 19% w/w of an adhesive polymer selected from the group consisting of polyvinylpyrrolidone, cellulose acetate phthalate, hydroxypropylcellulose and methylcellulose; (iv) of from about 1 to about 16% w/w of a disintegrant selected from the group consisting of starch and modified starches, microcrystalline cellulose and propylene glycol alginate;
b) wetting said blended ingredients with a liquid to cause the blend to stick together, wherein said liquid is selected from the group consisting of: 1%-25% w/w ethanol/75%-99% w/w 2- propanol/0.2%-2% w/w water; 98%-99% w/w 2- propanol/0.2%-2% w/w water; 1% -25% w/w methanol/0.2%-2% w/w water/75%-98% w/w 2 propanol/1%-5% w/w ethylacetate;
c) granulating or extruding the liquid-wetted blend through a 10 or 18 mesh S/S screen;
d) converting the granules to a uniform diameter particle size;
e) compacting the uniform particles to spherical particles;
f) drying the spherical particles;
g) separating the spherical particles if not of uniform size according to desired sizes using U.S. Standard sieve screens;
h) coating the particles with a gastric acid-resistant polymer that disintegrates under neutral or slightly basic conditions; and
i) drying the polymer-coated spherical particles.

### Claim 2 (depends on 1)

The process of claim 1 wherein said composition is in the form of microspheres having a mesh size of about 10 to 40.

### Claim 3 (depends on 1)

The process of claim 1 wherein said liquid for wetting the blended ingredient comprises from about 0.2% to about 2.5% moisture.

### Claim 4 (depends on 3)

The process of claim 3 wherein said moisture content is from 0.2 to 1.5%.

### Claim 5 (depends on 4)

The process of claim 4 wherein said moisture content is from 0.2 to 1.0%.

### Claim 6

A process for preparing a ursodeoxycholate composition for the treatment of ursodeoxycholic acid deficient mammals comprising the steps of:
a) preparing a starting seed of the ursodeoxycholate comprising: blending the powdery salt of ursodeoxycholic acid with a disintegrant and a buffering agent;
b) spraying said blend with a solution of an adhesive polymer until the blend agglomerates;
c) granulating or extruding the moistened blend through a 10 or 18 mesh S/S screen;
d) converting the granules to a uniform diameter particle size of 40 to 60 mesh;
e) compacting the uniform particles to spherical particles;
f) drying the spherical particles;
g) separating the spherical particles if not of uniform size according to desired sizes using U.S. Standard sieve screens;
h) employing said 40 to 60 mesh particles as starting seeds for the preparation of larger microspheres in the 10 to 20 mesh size range by placing the 40 to 60 mesh starting seeds in a rotating coating pan, spraying the microspheres with a liquid/adhesive polymer-containing mixture, followed by slowly dusting the buffered Na-ursodeoxycholic acid/disintegrant composition over the tumbling and flowing starting seeds until the desired particle sizes are obtained;
i) coating the particles with a gastric acid-resistant polymer that dissolves under neutral or slightly basic conditions; and
j) drying the polymer-coated spherical particles.

### Claim 7 (depends on 6)

The process of claim 6 wherein the particle size range of said seed is from about 20 to about 40 mesh.

### Claim 8 (depends on 6)

The process of claim 6 wherein said starting seed is selected from the group consisting of: sodium, potassium and ammonium salts of ursodeoxycholic acid; sodium, potassium and ammonium salts of glycyl and tauroursodeoxycholate; sodium and potassium salts of N-methylglycyl and N-methyl tauroursodeoxycholate.

### Claim 9 (depends on 6)

The process of claim 6 wherein the polymer-coated spherical particles are of 10 to 20 mesh.

### Claim 10 (depends on 1)

A method for treating ursodeoxycholic acid deficiency in mammals comprising: orally administering an effective amount of the composition prepared by the process of claim 1.

### Claim 11 (depends on 6)

A method for treating ursodeoxycholic acid deficiency in mammals comprising: orally administering an effective amount of the composition prepared by the process of claim 6.